Shandong Xinhua Pharmaceutical Co., Ltd. (hereinafter referred to as "Xinhua Pharmaceutical" or "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, with no false records, misleading statements, or significant omissions. Recently, Xinhua Pharmaceutical received the drug registration certificate for Sodium-Potassium-Magnesium-Calcium Injection Concentrate (hereinafter referred to as "the product") issued by the National Medical Products Administration. The relevant information is announced as follows:
000756SZSE
Announcement on Obtaining the Drug Registration Certificate for Sodium-Potassium-Magnesium-Calcium Injection Concentrate
✨ AI Summary
Shandong Xinhua Pharmaceutical Co., Ltd. has received the drug registration certificate for Sodium-Potassium-Magnesium-Calcium Injection Concentrate from the National Medical Products Administration. This approval allows the company to produce and sell the drug domestically. The product aims to maintain electrolyte balance in adult patients during intravenous infusion. The company warns investors of potential market uncertainties affecting drug sales.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.